| onfasprodil intravenous (MIJ821 IV) / Novartis |
2021-005992-38: Study of efficacy, safety, tolerability and pharmacokinetics of MIJ821 in participants with treatment- resistant depression (TRD) Estudio de eficacia, seguridad, tolerabilidad y farmacocinética de MIJ821 en participantes con depresión resistente al tratamiento (DRT). |
|
|
| Ongoing | 2 | 56 | Europe | MIJ821, MIJ821, Powder for solution for injection/infusion | Novartis Farmacéutica, S.A., Novartis Pharma AG | Treatment Resistant Depression Depresión resistente al tratamiento., Depression Depresión, Psychiatry and Psychology [F] - Psychological processes [F02] | | | | |
NCT04722666: Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent |
|
|
| Terminated | 2 | 200 | Europe, Canada, Japan, US, RoW | MIJ821 Intravenous Injection, Placebo Intravenous Injection | Novartis Pharmaceuticals | Major Depressive Disorder With Suicidal Ideation With Intent | 09/23 | 09/23 | | |
2020-003720-16: Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intent |
|
|
| Not yet recruiting | 2 | 195 | Europe | MIJ821, MIJ821, Powder for solution for injection/infusion | Novartis Pharma AG, Novartis Pharma AG | Major Depressive Disorder with suicidal ideation with intent, Major Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT05666687: An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain |
|
|
| Completed | 1 | 10 | Europe | MIJ821 | Novartis Pharmaceuticals | Major Depressive Disorder | 11/23 | 11/23 | | |
